One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species?

Journal of Pineal Research

Volumn 42, Issue 1, 2007, Pages 28-42

  Tan, Dun Xian ^a   Manchester, Lucien C ^a   Terron, Maria P ^a   Flores, Luis J ^a   Reiter, Russel J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antioxidants; Bioavailability; Free radical; Melatonin; Metabolism; Oxidative metabolites; Synthetic regulation

Indexed keywords

3 HYDROXYMELATONIN; 6 HYDROXYMELATONIN O SULFATE; ANTIOXIDANT; ENZYME; KYNURAMINE; MELATONIN; MELATONIN DERIVATIVE; N1 ACETYL N2 FORMYL 5 METHOXYKYNURAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCAVENGER;

ANTIOXIDANT ACTIVITY; BRAIN; DIET RESTRICTION; EXERCISE; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; MAMMAL; METAZOON; MOLECULAR EVOLUTION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PROKARYOTIC CELL; SCAVENGING SYSTEM; SHORT SURVEY; SKIN; TISSUE DISTRIBUTION; ULTRAVIOLET IRRADIATION;

ANIMALS; BIOLOGICAL AVAILABILITY; HUMANS; KYNURAMINE; MELATONIN;

EID: 33845536018     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2006.00407.x     Document Type: Short Survey

References (155)

1. LERNER AB, CASE JD, TAKAHASHI Y. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc 1958; 80:2587.
2. MARCZYNSKI TJ, YAMAGUCHI N, LING GM, GRODZINSKA L. Sleep induced by the administration of melatonin (5-methoxyn-acetyltryptamine) to the hypothalamus in unrestrained cats. Experientia 1964; 20:435-437.
3. REITER RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991; 79:C153-C158.
4. REITER RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 199; 12:151-180.
5. REITER RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49:654-664.
6. TAN DX, CHEN LD, POEGGELER B, MANCHESTER LC, REITER RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
7. TAN DX, REITER RJ, MANCHESTER LC et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-197.
8. MISHIMA K, TOZAWA T, SATOH K, MATSUMOTO Y, HISHIKAWA Y, OKAWA M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 1999; 45:417-421.
9. LIU RY, ZHOU JN, VAN HEERIKHUIZE J, HOFMAN MA, SWAAB DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999; 84:323-327.
10. SAKOTNIK A, LIEBMANN PM, STOSCHITZKY K et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999; 20:1314-1317.
11. ALTUN A, YAPRAK M, AKTOZ M, VARDAR A, BETUL UA, OZBAY G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002; 327:143-145.
12. DOMINGUEZ-RODRIGUEZ A, ABREU-GONZALEZ P, GARCIA MJ, SANCHEZ J, MARRERO F, DE ARMAS-TRUJILLO D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 2002; 33:248-252.
13. YAPRAK M, ALTUN A, VARDAR A, AKTOZ M, CIFTCI S, OZBAY G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 2003; 89:103-107.
14. HARDELAND R, REITER RJ, POEGGELER B, TAN DX. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993; 17:347-357.
15. VOLLRATH L, HUESGEN A. Response of pineal serotonin N-acetyltransferase activity in male guinea pigs exposed to light pulses at night. J Neural Transm 1988; 72:55-66.
16. FOULKES NS, WHITMORE D, SASSONE-CORSI P. Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Biol Cell 1997; 89:487-494.
17. KAROLCZAK M, KORF HW, STEHLE JH. The rhythm and blues of gene expression in the rodent pineal gland. Endocrine 2005; 27:89-100.
18. RIBELAYGA C, PEVET P, SIMONNEAUX V. HIOMT drives the photoperiodic changes in the amplitude of the melatonin peak of the Siberian hamster. Am J Physiol Regul Integr Comp Physiol 2000; 278:R1339-R1345.
19. CEINOS RM, CHANSARD M, REVEL F, CALGARI C, MIGUEZ JM, SIMONNEAUX V. Analysis of adrenergic regulation of melatonin synthesis in Siberian hamster pineal emphasizes the role of HIOMT. Neurosignals 2004; 13:308-317.
20. JOHNSTON JD, BASHFORTH R, DIACK A, ANDERSSON H, LINCOLN GA, HAZLERIGG DG. Rhythmic melatonin secretion does not correlate with the expression of arylalkylamine N-acetyltransferase, inducible cyclic AMP early repressor, period1 or cryptochrome1 mRNA in the sheep pineal. Neuroscience 2004; 124:789-795.
21. LIU T, BORJIGIN J. N-acetyltransferase is not the rate-limiting enzyme of melatonin synthesis at night. J Pineal Res 2005; 39:91-96.
22. HARDELAND R., POEGGELER B. Non-vertebrate melatonin. J Pineal Res 2003; 34:233-241.
23. IUVONE PM, BESHARSE JC. Regulation of indoleamine N-acetyltransferase activity in the retina: effects of light and dark, protein synthesis inhibitors and cyclic nucleotide analogs. Brain Res 1983; 273:111-119.
24. MARTIN XD, MALINA HZ, BRENNAN MC, HENDRICKSON PH, LICHTER PR. The ciliary body - the third organ found to synthesize indoleamines in humans. Eur J Ophthalmol 1992; 2:67-72.
25. ABE M, ITOH MT, MIYATA M, ISHIKAWA S, SUMI Y. Detection of melatonin, its precursors and related enzyme activities in rabbit lens. Exp Eye Res 1999; 68:255-262.
26. MENENDEZ-PELAEZ A, HOWES KA, GONZALEZ-BRITO A, REITER RJ. N-acetyltransferase activity, hydroxyindole-O-methyltransferase activity, and melatonin levels in the Harderian glands of the female Syrian hamster: changes during the light:dark cycle and the effect of 6-parachlorophenylalanine administration. Biochem Biophys Res Commun 1987; 145:1231-1238.
27. STEFULJ J, HORTNER M, GHOSH M et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res 2001; 30:243-247.
28. JIMENEZ-JORGE S, JIMENEZ-CALIANI AJ, GUERRERO JM et al. Melatonin synthesis and melatonin-membrane receptor (MT1) expression during rat thymus development: role of the pineal gland. J Pineal Res 2005; 39:77-83.
29. KVETNOY IM. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem J 1999; 31:1-12.
30. TAN DX, MANCHESTER LC, REITER RJ et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999; 1472:206-214.
31. CONTI A, CONCONI S, HERTENS E, SKWARLO-SONTA K, MARKOWSKA M, MAESTRONI JM. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000; 28:193-202.
32. HUETHER G, POEGGELER B, REIMER A, GEORGE A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992; 51:945-953.
33. HUETHER G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 1993; 49:665-670.
34. ITOH MT, ISHIZUKA B, KURIBAYASHI Y, AMEMIYA A, SUMI Y. Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol Hum Reprod 1999; 5:402-408.
35. TIJMES M, PEDRAZA R, VALLADARES L. Melatonin in the rat testis: evidence for local synthesis. Steroids 1996; 61:65-68.
36. IWASAKI S, NAKAZAWA K, SAKAI J et al. Melatonin as a local regulator of human placental function. J Pineal Res 2005; 39:261-265.
37. CARRILLO-VICO A, CALVO JR, ABREU P et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18:537-539.
38. FISCHER TW, SWEATMAN TW, SEMAK I, SAYRE RM, WORTSMAN J, SLOMINSKI A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J 2006; 20:1564-1566.
39. TAN DX, MANCHESTER LC, REITER RJ, QI W, HANES MA, FARLEY NJ. High physiological levels of melatonin in the bile of mammals. Life Sci 1999; 65:2523-2529.
40. SKINNER DC, MALPAUX B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 1999; 140:4399-4405.
41. TRICOIRE H, LOCATELLI A, CHEMINEAU P, MALPAUX B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002; 143:84-90.
42. WATT FM, JORDAN PW, O'NEILL CH. Cell shape controls terminal differentiation of human epidermal keratinocytes. Proc Natl Acad Sci U S A 1988; 85:5576-5580.
43. SAVINI I, DUFLOT S, AVIGLIANO L. Dehydroascorbic acid uptake in a human keratinocyte cell line (HaCaT) is glutathione-independent. Biochem J 2000; 345:665-672.
44. CHEN G, HUO Y, TAN DX, LIANG Z, ZHANG W, ZHANG Y. Melatonin in Chinese medicinal herbs. Life Sci 2003; 73:19-26.
45. VAKKURI O, RINTAMAKI H, LEPPALUOTO J. Plasma and tissue concentrations of melatonin after midnight light exposure and pinealectomy in the pigeon. J Endocrinol 1985; 105:263-268.
46. VAUGHAN GM, REITER RJ. Pineal dependence of the Syrian hamster's nocturnal serum melatonin surge. J Pineal Res 1986; 3:9-14.
47. TAN DX, MANCHESTER LC, HARDELAND R et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34:75-78.
48. LAHIRI DK, DAVIS D, NURNBERGER JI, Jr. Detection of specific protein bands with melatonin-like immunoreactivity in different cell lines and human brain regions. IUBMB Life 1999; 48:127-132.
49. STOKKAN KA, REITER RJ, NONAKA KO, LERCHL A, YU BP, VAUGHAN MK. Food restriction retards aging of the pineal gland. Brain Res 1991; 545:66-72.
50. MATTISON JA, LANE MA, ROTH GS, INGRAM DK. Calorie restriction in rhesus monkeys. Exp Gerontol 2003; 38:35-46.
51. ROTH GS, HANDY AM, MATTISON JA, TILMONT EM, INGRAM DK, LANE MA. Effects of dietary caloric restriction and aging on thyroidhormones of rhesus monkeys. Horm Metab Res 2002; 34:378-382.
52. FUHRBERG B, HARDELAND R, POEGGELER B, BEHRMANN G. Dramatic rises of melatonin and 5-methoxytryptamine in Gonyaulax exposed to decreased temperature. Biol Rhythm Res 1997; 28:144-150.
53. TAN DX, MANCHESTER LC, REITER RJ, QI W, KARBOWNIK M, CALVO JR. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000; 9:137-159.
54. LEE PP, ALLEN AE, PANG SF. Cold stress during scotophase elicited differential response in quail pineal, retinal, and serum melatonin levels. Acta Endocrinol 1990; 122:535-539.
55. WU WT, CHEN YC, REITER RJ. Day-night differences in the responses of the pineal gland to swimming stress. Proc Soc Exp Biol Med 1988; 187:315-319.
56. CARR DB, REPPERT SM, BULLEN B et al. Plasma melatonin increases during exercise in women. J Clin Endocrinol Metab 1981; 53:224-225.
57. BULLEN BA, SKRINAR GS, MCARTHUR JW, CARR DB. Exercise effect upon plasma melatonin levels in women: possible physiological significance. Can J Appl Sport Sci 1982; 7:90-97.
58. JAWOREK J, LEJA-SZPAK A, BONIOR J et al. Protective effect of melatonin and its precursor L-tryptophan on acute pancreatitis induced by caerulein overstimulation or ischemia/reperfusion. J Pineal Res 2003; 34:40-52.
59. AFREEN F, ZOBAYED SM, KOZAI T. Melatonin in Glycyrrhiza uralensis: response of plant roots to spectral quality of light and UV-B radiation. J Pineal Res 2006; 41:108-115.
60. RODRIGUEZ JR, MAZURUK K, SCHOEN TJ, CHADER GJ. Structural analysis of the human hydroxyindole-O-methyltransferase gene. Presence of two distinct promoters. J Biol Chem 1994; 269:3169-3177.
61. ESTRADA-RODGERS L, LEVY GN, WEBER WW. Characterization of a hormone response element in the mouse N-acetyltransferase 2 (NAT2*) promoter. Gene Exp 1998; 7:13-24.
62. SCORTEGANA M, GALDZICKI Z, RAPOPORT SI, HANBAVER J. Activator protein 1 DNA binding activation by hydrogen peroxide in neuronal and astrocytic primary cultures of trisomy-16 and diploid mice. Brain Res Mol Brain Res 1999; 73:144-150.
63. SEEMATTER G, BINNERT C, MARTIN JL, TAPPY L. Relationship between stress, inflammation and metabolism. Curr Opin Clin Nutr Metab Care 2004; 7:169-173.
64. OTSUKA M, KATO K, MURAI I, ASAI S, IWASAKI A, AREKAWA Y. Role of nocturnal melatonin and the pineal gland in modulation of water-immersion restraint stress-induced gastric mucosal lesions in rats. J Pineal Res 2001; 30:82-86.
65. TAN DX, MANCHESTER LC, REITER RJ, QI W, KIM SJ, EL-SOKKARY GH. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res 1998; 25:184-191.
66. SAHNA E, OLMEZ E, ACET A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? J Pineal Res 2002; 32:194-198.
67. SAHNA E, PARLAKPINAR H, TURKOZ Y, ACET A. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. Physiol Res 2005; 54:491-495.
68. WU WT, REITER RJ, TROIANI ME, VAUGHAN GM. Elevated daytime rat pineal and serum melatonin levels induced by isoproterenol are depressed by swimming. Life Sci 1987; 41:1473-1479.
69. WU WT, CHEN YC, SABRY I, REITER RJ. Evidence that the deep pineal gland of the rat responds to isoperoterenol and to swimming stress. Neuroendocrinol Lett 1988; 10:19-25.
70. UECK M, TROIANI ME, REITER RJ. Transient reduction in pineal melatonin levels but not N-acetyltransferase activity in rats forced to swim for 15 minutes at night. Neuroendocrinol Lett 1988; 10:81-89.
71. TROIANI ME, REITER RJ, VAUGHAN MK, OAKNIN S, VAUGHAN GM. Swimming depresses nighttime melatonin content without changing N-acetyltransferase activity in the rat pineal gland. Neuroendocrinology 1988; 47:55-60.
72. TROIANI ME, REITER RJ, TANNENBAUM MG, PUIG-DOMINGO M, GUERRERO JM, MENENDEZ-PELAEZ A. Neither the pituitary gland nor the sympathetic nervous system is responsible for eliciting the large drop in elevated rat pineal melatonin levels due to swimming. J Neural Transm 1988; 74:149-160.
73. POHJANVIRTA R, TUOMISTO J, LINDEN J, LAITINEN J. TCDD reduces serum melatonin levels in Long-Evans rats. Pharmacol Toxicol 1989; 65:239-240.
74. LINDEN J, POHJANVIRTA R, RAHKO T, TUOMISTO J. TCDD decreases rapidly and persistently serum melatonin concentration without morphologically affecting the pineal gland in TCDD-resistant Han/Wistar rats. Pharmacol Toxicol 1991; 69:427-432.
75. POHJANVIRTA R, LAITINEN J, VAKKURI O et al. Mechanism by which 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) reduces circulating melatonin levels in the rat. Toxicology 1996; 107:85-97.
76. SLEZAK BP, HAMM JT, REYNA J, HURST CH, BIRNBAUM LS. TCDD-mediated oxidative stress in male rat pups following perinatal exposure. J Biochem Mol Toxicol 2002; 16:49-52.
77. KNERR S, SCHAEFER J, BOTH S, MALLY A, DEKANT W, SCHRENK D. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induced cytochrome P450s alter the formation of reactive oxygen species in liver cells. Mol Nutr Food Res 2006; 50:378-384.
78. TAN DX, MANCHESTER LC, REITER RJ et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998; 253:614-620.
79. MA X, IDLE JR, KRAUSZ KW, GONZALEZ FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 2005; 33:489-494.
80. LAHIRI DK, GE YW, SHARMAN EH, BONDY SC. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J Pineal Res 2004; 36:217-223.
81. AUST S, JAEGER W, KLIMPFINGER M et al. Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1. J Pineal Res 2005; 39:276-282.
82. ZHANG H, SQUADRITO GL, PRYOR WA. The reaction of melatonin with peroxynitrite: formation of melatonin radical cation and absence of stable nitrated products. Biochem Biophys Res Commun 1998; 251:83-87.
83. ZHANG H, SQUADRITO GL, UPPU R, PRYOR WA. Reaction of peroxynitrite with melatonin: a mechanistic study. Chem Res Toxicol 1999; 12:526-534.
84. HORSTMAN JA, WRONA MZ, DRYHURST G. Further insights into the reaction of melatonin with hydroxyl radical. Bioorg Chem 2002; 30:371-382.
85. DELLEGAR SM, MURPHY SA, BOURNE AE, DICESARE JC, PURSER GH. Identification of the factors affecting the rate of deactivation of hypochlorous acid by melatonin. Biochem Biophys Res Commun 1999; 257:431-439.
86. AGOZZINO P, AVELLONE G, BONGIORNO D et al. Melatonin: structural characterization of its non-enzymatic mono-oxygenate metabolite. J Pineal Res 2003; 35:269-275.
87. SEMAK I, NAUMOVA M, KORIK E, TEREKHOVICH V, WORTSMAN J, SLOMINSKI A. A novel metabolic pathway of melatonin: oxidation by cytochrome C. Biochemistry 2005; 44:9300-9307.
88. MA X, IDLE JR, KRAUSZ KW, TAN DX, CERAULO L, GONZALEZ FJ. Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. J Pineal Res 2006; 40:343-349.
89. 2 content. Eur J Org Chem 2002; 321:1-10.
90. TESORIERE L, AVELLONE G, CERAULO L, D'ARPA D, ALLEGRA M, LIVREA MA. Oxidation of melatonin by oxoferryl hemoglobin: a mechanistic study. Free Radic Res 2001; 35:633-642.
91. TAN DX, HARDELAND R, MANCHESTER LC et al. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J Pineal Res 2003; 34:249-259.
92. SIWICKA A, REITER RJ, TAN X et al. The synthesis and the structure elucidation of N, O-diacetyl derivative of cyclic 3-hydroxymelatonin. Central Eur J Chem 2004; 2:425-433.
93. HIRATA F, HAYAISHI O, TOKUYAMA T, SENO S. In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 1974; 249:1311-1313.
94. TAN DX, MANCHESTER LC, REITER RJ et al. Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med 2000; 29:1177-1185.
95. XIMENES VF, CATALANI LH, CAMPA A. Oxidation of melatonin and tryptophan by an HRP cycle involving compound III. Biochem Biophys Res Commun 2001; 287:130-134.
96. SILVA SO, XIMENES VF, CATALANI LH, CAMPA A. Myeloperoxidase-catalyzed oxidation of melatonin by activated neutrophils. Biochem Biophys Res Commun 2000; 279:657-662.
97. HARDELAND R, PANDI-PERUMAL SR, CARDINALI DP. Melatonin. Int J Biochem Cell Biol 2006; 38:313-316.
98. HARDELAND R, BALZER I, POEGGELER B et al. On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals. J Pineal Res 1995; 18:104-111.
99. g)) produces N1-acetyl-N2-formyl-5- methoxykynurenine. J Pineal Res 2003; 35:131-137.
100. HARDELAND R, POEGGELER B, NIEBERGALL R, ZELOSKO V. Oxidation of melatonin by carbonate radicals and chemiluminescence emitted during pyrrole ring cleavage. J Pineal Res 2003; 34:17-25.
101. RODRIGUES MR, RODRIGUEZ D, HENRIQUE CATALANI L, RUSSO M, CAMPA A. Interferon-gamma independent oxidation of melatonin by macrophages. J Pineal Res 2003; 34:69-74.
102. SILVA SO, RODRIGUES MR, CARVALHO SR, CATALANI LH, CAMPA A, XIMENES VF. Oxidation of melatonin and its catabolites, N1-acetyl-N2 -formyl-5- methoxykynuramine and N1-acetyl-5-methoxykynuramine, by activated leukocytes. J Pineal Res 2004; 37:171-175.
103. SILVA SO, CARVALHO SR, XIMENES VF, OKADA SS, CAMPA A. Melatonin and its kynurenin-like oxidation products affect the microbicidal activity of neutrophils. Microbes Infect 2006; 8:420-425.
104. POEGGELER B, HARDELAND R. Observations on melatonin oxidation and metabolite release by unicellular organisms and small aquatic metazoans. In: Actions and Redox Properties of Melatonin and other Aromatic Amino Acid Metabolites. Hardeland R, ed. Cuviller Verlag, Gottingen, 2001; pp. 66-69.
105. ROZOV SV, FILATOVA EV, ORLOV AA et al. N1-acetyl-N2-formyl-5 methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res 2003; 35:245-250.
106. HARTHE C, CLAUDY D, DECHAUD H, VIVIEN-ROELS B, PEVET P, CLAUSTRAT B. Radioimmunoassay of N-acetyl-N-formyl-5-methoxykynuramine (AFMK): a melatonin oxidative metabolite. Life Sci 2003; 73:1587-1597.
107. 2-formyl-5-methoxykynuramine, in cerebrospinal fluid of patients with meningitis: a possible immunomodulatory mechanism. J Pineal Res 2005; 39:302-306.
108. ROSEN J, THAN NN, KOCH D, POEGGELER B, LAATSCH H, HARDELAND R. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res 2006; 41:374-381.
109. THAN NN, HEER C, LAATSCH H, HARDELAND R. Reactions of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) with the ABTS cation radical: identification of new oxidation products. Redox Rep 2006; 11:15-24.
110. GUENTHER AL, SCHMIDT SI, LAATSCH H et al. Reactions of the melatonin metabolite AMK (N1-acetyl-5-methoxykynuramine) with reactive nitrogen species: formation of novel compounds, 3-acetamidomethyl-6-methoxycinnolinone and 3-nitro-AMK. J Pineal Res 2005; 39:251-260.
111. BLANCHARD B, POMPON D, DUCROCQ C. Nitrosation of melatonin by nitric oxide and peroxynitrite. J Pineal Res 2000; 29:184-192.
112. PEYROT F, FERNANDEZ BO, BRYAN NS, FEELISCH M, DUCROCQ C. N-Nitroso products from the reaction of indoles with Angeli's salt. Chem Res Toxicol 2006; 19:58-67.
113. .; comparison with the peroxynitrite reaction. Free Radic Res 2006; 40:910-920.
114. BUDU A, PERES R, BUENO VB, CATALANI LH, DA SILVA GARCIA CR. N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) modulates the cell cycle of malaria parasites. J Pineal Res 2007; in press.
115. BONN D. Melatonin' multifarious marvel: miracle or myth? Lancet 1996; 347:184.
116. FOURTILLAN JB, BRISSON AM, GOBIN P, INGRAND I, DECOURT JP, GIRAULT J. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos 2000; 21:15-22.
117. MESSNER M, HUETHER G, LORF T, RAMADORI G, SCHWORER H. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69:543-551.
118. WALDHAUSER F, WALDHAUSER M, LIEBERMAN HR, DENG MH, LYNCH HJ, WURTMAN RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39:307-313.
119. DI WL, KADVA A, JOHNSTON A, SILMAN R. Variable bioavailability of oral melatonin. N Engl J Med 1997; 336:1028-1029.
120. DEMURO RL, NAFZIGER AN, BLASK DE, MENHINICK AM, BERTINO JS, Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000; 40:781-784.
121. LANE EA, MOSS HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61:1214-1216.
122. HARTTER S, GROZINGER M, WEIGMANN H, ROSCHKE J, HIEMKE C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000; 67:1-6.
123. HATTER S, NORDMARK A, ROSE DM, BERTILSSON L, TYBRING G, LAINE K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol 2003; 56:679-682.
124. MANCHESTER LC, POEGGELER B, ALVARES FL, OGDEN GB, REITER RJ. Melatonin immunoreactivity in the photosynthetic prokaryote Rhodospirillum rubrum: implications for an ancient antioxidant system. Cell Mol Biol Res 1995; 41:391-395.
125. POEGGELER B, BALZER I, HARDELAND R, LERCHL A. Pineal hormone melatonin oscillates also in the dinoflagellate Gonyaulax polyedra. Naturwissenschaften 1991; 78:268-269.
126. SPRENGER J, HARDELAND R, FUHRBERG B, HAN SZ. Melatonin and other 5-methoxylated indoles in yeast: presence in high concentrations and dependence on tryptophan availability. Cytologia 1999; 64:209-213.
127. REITER RJ. Melatonin, active oxygen species and neurological damage. Drug News Perspect 1998; 11:291-296.
128. TAN DX, MANCHESTER LC, REITER RJ, QI WB, KARBOWNIK M, CALVO JR. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000; 9:137-159.
129. HARDELAND R, PANDI-PERUMAL SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005; 2:1-15.
130. HARDELAND R, COTO-MONTES A, POEGGELER B. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol Int 2003; 20:921-962.
131. HARA M, IIGO M, OHTANI-KANEKO R et al. Administration of melatonin and related indoles prevents exercise-induced cellular oxidative changes in rats. Biol Signals 1997; 6:90-100.
132. QI W, REITER RJ, TAN DX, MANCHESTER LC, SIU AW, GARCIA JJ. Increased levels of oxidatively damaged DNA induced by chromium(III) and H2O2: protection by melatonin and related molecules. J Pineal Res 2000; 29:54-61.
133. 2-formyl-5-methoxykynuramine and 6-hydroxymelatonin reduce oxidative DNA damage induced by Fenton reagents. J Pineal Res 2003; 34:178-184.
134. HARA M, YOSHIDA M, NISHIJIMA H et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001; 30:129-138.
135. MAHARAJ DS, WALKER RB, GLASS BD, DAYA S. 6-Hydroxymelatonin protects against cyanide induced oxidative stress in rat brain homogenates. J Chem Neuroanat 2003; 26:103-107.
136. MAHARAJ DS, MAHARAJ H, ANTUNES EM et al. 6-Hydroxymelatonin protects against quinolinic-acid-induced oxidative neurotoxicity in the rat hippocampus. J Pharm Pharmacol 2005; 57:877-881.
137. MAHARAJ DS, MAHARAJ H, DAYA S, GLASS BD. Melatonin and 6-hydroxymelatonin protect against iron-induced neurotoxicity. J Neurochem 2006; 96:78-81.
138. CALVO JR, REITER RJ, GARCIA JJ, ORTIZ GG, TAN DX, KARBOWNIK M. Characterization of the protective effects of melatonin and related indoles against alpha-naphthylisothiocyanate-induced liver injury in rats. J Cell Biochem 2001; 80:461-470.
139. MATUSZAK Z, BILSKA MA, RESZKA KJ, CHIGNELL CF, BILSKI P. Interaction of singlet molecular oxygen with melatonin and related indoles. Photochem Photobiol 2003; 78:449-455.
140. MAHARAJ DS, LIMSON JL, DAYA S. Hydroxymelatonin converts Fe(III) to Fe(II) and reduces iron-induced lipid peroxidation. Life Sci 2003; 72:1367-1375.
141. LIU X, CHEN Z, CHUA CC et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2002; 283:H254-H263.
142. DUAN Q, WANG Z, LU T, CHEN J, WANG X. Comparison of 6-hydroxylmelatonin or melatonin in protecting neurons against ischemia/reperfusion-mediated injury. J Pineal Res 2006; 41:351-357.
143. SAKANO K, OIKAWA S, HIRAKU Y, KAWANISHI S. Oxidative DNA damage induced by a melatonin metabolite, 6-hydroxymelatonin, via a unique non-o-quinone type of redox cycle. Biochem Pharmacol 2004; 68:1869-1878.
144. 2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 2001; 15:2294-2296.
145. MAHARAJ DS, ANOOPKUMAR-DUKIE S, GLASS BD et al. The identification of the UV degradants of melatonin and their ability to scavenge free radicals. J Pineal Res 2002; 32:257-261.
146. 2-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol 2001; 33:775-783.
147. ONUKI J, ALMEIDA EA, MEDEIROS MH, DI MASCIO P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5- methoxykynuramine, quercetin or resveratrol. J Pineal Res 2005; 38:107-115.
148. 1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003; 8:205-213.
149. ENTRENA A, CAMACHO ME, CARRION MD et al. Kynurenamines as neural nitric oxide synthase inhibitors. J Med Chem 2005; 48:8174-8181.
150. 1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem 2006; 98:2023-2033.
151. HARDELAND R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27:119-130.
152. ACUNA-CASTROVIEJO D, ESCAMES G, LEON J, CARAZO A, KHALDY H. Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003; 527:549-557.
153. KELLY RW, AMATO F, SEAMARK RF. N-acetyl-5-methoxy kynurenamine, a brain metabolite of melatonin, is a potent inhibitor of prostaglandin biosynthesis. Biochem Biophys Res Commun 1984; 121:372-379.
154. SILVA SO, RODRIGUES MR, XIMENES VF, BUENO-DA-SILVA AE, AMARANTE-MENDES GP, CAMPA A. Neutrophils as a specific target for melatonin and kynuramines: effects on cytokine release. J Neuroimmunol 2004; 156:146-152.
155. 1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005; 165:139-149.